Compare RVSB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | NYXH |
|---|---|---|
| Founded | 1923 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 126.0M |
| IPO Year | 1997 | 2021 |
| Metric | RVSB | NYXH |
|---|---|---|
| Price | $5.75 | $1.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $9.33 |
| AVG Volume (30 Days) | 41.2K | ★ 490.0K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.63 | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $1.26 |
| 52 Week High | $6.22 | $8.59 |
| Indicator | RVSB | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 31.52 |
| Support Level | $4.96 | $1.26 |
| Resistance Level | $6.22 | $3.43 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 43.24 | 18.89 |
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.